Ascendis Pharma A/s

This study tests a weekly injection called navepegritide in 24 adolescents aged 12-18 with achondroplasia, the most common form of dwarfism. The goal is to see if it safely increases growth rate over one year compared to a placebo. Participants will receive either the drug or an …

This study tests if a once-weekly growth hormone injection works as well as a daily one in children with short stature due to Turner syndrome, SHOX deficiency, being small at birth, or unknown causes. About 186 children will receive either the weekly or daily treatment for up to …

This study tests a weekly injection called TransCon CNP in infants under 2 years old with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth compared to a placebo. About 72 babies will take part, receiving either the drug or a dummy …

This study looks at how much of the drug palopegteriparatide (YORVIPATH) passes into breast milk. It involves 10 lactating women with hypoparathyroidism who are already taking the drug and choose to breastfeed. Researchers will collect milk samples to measure drug levels, helping…

This study is a pregnancy registry that collects information from women aged 15 to 50 who took YORVIPATH for hypoparathyroidism around the time of conception or during pregnancy. Researchers will track pregnancy complications, birth outcomes, and infant health for at least one ye…